Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987462 | 0.80 | ENPP2 (0.31) | ENPP2CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL3986318 | 0.78 | DRD3 (0.33) | MAPTTP53SMN1; SMN2NPSR1NPC1 | |
| SCHEMBL3992089 | 0.77 | MAPT (0.41) | MAPTTP53POLBKMT2AMEN1 | |
| SCHEMBL3986313 | 0.75 | MAPK1 (0.42) | MAPTTP53POLBMAPK1ALDH1A1 | |
| SCHEMBL3990996 | 0.74 | MAPK1 (0.46) | MAPTTP53POLBKMT2AMEN1 | |
| SCHEMBL24287495 | 0.73 | MAPT (0.40) | MAPTTP53KMT2AMEN1MAPK1 | |
| SCHEMBL26820165 | 0.72 | NPSR1 (0.43) | MAPTTP53POLBKMT2AMEN1 | |
| SCHEMBL3536479 | 0.70 | MAPT (0.57) | MAPTTP53POLBSMN1; SMN2NPSR1 | |
| SCHEMBL13314763 | 0.70 | MAPT (0.57) | MAPTTP53POLBSMN1; SMN2NPSR1 | |
| SCHEMBL4704559 | 0.67 | RORC (0.40) | MAPTTP53POLBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | claimed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
| JP-2007504176-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1663993-A1 | GUANIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023781-A1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-03-17 | — | — | WO | claimed |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015120446-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULENESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-08-13 | — | — | WO | disclosed |
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | disclosed |
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | disclosed |
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| EP-1663993-A1 | GUANIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023781-A1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | MAPT 1674/4885TP53 3166/4885POLB 1126/4885 |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | MAPT 2646/4885TP53 4839/4885POLB 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.